Blue Edge Capital’s AbbVie ABBV Stock Holding History

Blue Edge Capital’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.18M	Sell	4,709 -2,055	-30%	-$442K	0.14%	77
2026 Q1	$1.47M	Buy	6,764 +390	+6%	+$86.5K	0.2%	69
2025 Q4	$1.46M	Sell	6,374 -100	-2%	-$22.8K	0.19%	66
2025 Q3	$1.5M	Hold	6,474	–	–	0.21%	67
2025 Q2	$1.2M	Sell	6,474 -237	-4%	-$44K	0.18%	72
2025 Q1	$1.41M	Buy	6,711 +2	+0%	+$389	0.23%	66
2024 Q4	$1.19M	Buy	6,709 +2	+0%	+$368	0.19%	68
2024 Q3	$1.32M	Buy	6,707 +1,483	+28%	+$277K	0.21%	66
2024 Q2	$896K	Hold	5,224	–	–	0.15%	73
2024 Q1	$951K	Hold	5,224	–	–	0.16%	75
2023 Q4	$809K	Hold	5,224	–	–	0.15%	75
2023 Q3	$779K	Hold	5,224	–	–	0.16%	73
2023 Q2	$704K	Hold	5,224	–	–	0.14%	74
2023 Q1	$832K	Hold	5,224	–	–	0.18%	69
2022 Q4	$844K	Buy	5,224 +1	+0%	+$153	0.19%	70
2022 Q3	$701K	Sell	5,223 -1	-0%	-$143	0.17%	72
2022 Q2	$800K	Sell	5,224 -184	-3%	-$28.1K	0.19%	71
2022 Q1	$877K	Buy	5,408 +184	+4%	+$26.7K	0.18%	74
2021 Q4	$707K	Hold	5,224	–	–	0.14%	78
2021 Q3	$563K	Buy	5,224 +1	+0%	+$114	0.12%	75
2021 Q2	$588K	Sell	5,223 -1	-0%	-$113	0.12%	78
2021 Q1	$565K	Hold	5,224	–	–	0.13%	75
2020 Q4	$560K	Hold	5,224	–	–	0.14%	78
2020 Q3	$458K	Sell	5,224 -175	-3%	-$16.5K	0.12%	74
2020 Q2	$530K	Buy	5,399 +175	+3%	+$15.4K	0.16%	70
2020 Q1	$398K	Buy	5,224 +2,400	+85%	+$204K	0.14%	79
2019 Q4	$232K	Hold	2,824	–	–	0.07%	91
2019 Q3	$214K	Hold	2,824	–	–	0.07%	90
2019 Q2	$205K	Hold	2,824	–	–	0.07%	88
2019 Q1	$228K	Buy	2,824 +3	+0.1%	+$245	0.09%	89
2018 Q4	$260K	Buy	2,821 +3	+0.1%	+$264	0.11%	81
2018 Q3	$267K	Buy	2,818 +2	+0.1%	+$190	0.1%	84
2018 Q2	$261K	Buy	2,816 +2	+0.1%	+$195	0.1%	82
2018 Q1	$266K	Sell	2,814 -299	-10%	-$32.8K	0.11%	82
2017 Q4	$301K	Buy	3,113 +301	+11%	+$28.4K	0.12%	81
2017 Q3	$250K	Buy	2,812 +2	+0.1%	+$152	0.11%	80
2017 Q2	$204K	Buy	+2,810	New	+$189K	0.1%	81

Other funds holding ABBV

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Blue Edge Capital's ABBV Position: Q2 2026 in Review

Blue Edge Capital reduced its AbbVie (ABBV) stake by 30% in Q2 2026, selling an estimated $442K and leaving 4,709 shares worth $1.18M. The position accounts for 0.14% of the portfolio, ranked #77.

Blue Edge Capital first reported a position in ABBV in Q2 2017 and has held it in 37 quarters since. The position peaked at $1.5M in Q3 2025. 4,201 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

Blue Edge Capital held 4,709 shares of AbbVie worth $1.18M as of Q2 2026.
Blue Edge Capital sold 2,055 AbbVie shares in Q2 2026, an estimated $442K.
AbbVie made up 0.14% of Blue Edge Capital's portfolio in Q2 2026, its #77 holding.
Blue Edge Capital first reported a position in AbbVie in Q2 2017 and has held it in 37 quarters since.
Blue Edge Capital's AbbVie position peaked at $1.5M in Q3 2025.
4,201 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Blue Edge Capital's 13F filing for Q2 2026, filed 17 Aug 2026.